Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Production & Manufacturing
Process & Production
Return to: PBR Home | Production & Manufacturing | Process & Production

Process & Production

Tribute Pharmaceuticals secures uracyst patent in Europe Tribute Pharmaceuticals Canada has received a patent approval from the European Patent Office (EPO) for intellectual property central to one of the Company's lead products, Uracyst/Uropol (a sterile sodium chondroitin sulfate solution, 2%), for the treatment of interstitial cystitis by instillation into the bladder of a patient.
Production & Manufacturing > Process & Production > News
Levolta receives US patent for new investigational therapy for controlling osteoarthritis Levolta Pharmaceuticals an emerging leader in developmental osteoarthritis (OA) therapy, has announced that the US Patent and Trademark Office has awarded the company a patent for its novel VOLT01, a derivative of zoledronic acid (ZA), a proposed commercial product that has shown promise as a disease-modifying drug in clinical trials.
Production & Manufacturing > Process & Production > News Kamada's Glassia gets FDA orphan drug status for GVHD treatment By PBR Staff Writer
Irish firm Kamada has received orphan drug designation from the US Food and Drug Administration’s (FDA) Office of Orphan Products Development for its human Alpha-1 Antitrypsin (AAT) Glassia, to treat immunologically-based graft versus host disease (GVHD).
Production & Manufacturing > Process & Production > News
See more Process & Production news

Latest Process & Production News and Insight

View all Process & Production news or find news targeted to your interests
FDA clears ProMetic's IND for plasminogen to treat hypoplasminogenemia
By PBR Staff Writer
The US Food and Drug Administration (FDA) has reviewed and cleared the investigational new drug (IND) application for Canada-based ProMetic Life Sciences' IV plasminogen to treat hypoplasminogenemia, or type I plasminogen deficiency.
Production & Manufacturing > Process & Production > News
FDA grants fast track status for Araim's ARA290 to treat Sarcoidosis-associated SFN
By PBR Staff Writer
The US Food and Drug Administration (FDA) has granted fast track designation for Araim Pharmaceuticals' lead compound ARA290, to treat Sarcoidosis-associated Small Fiber Neuropathy (SFN).
Production & Manufacturing > Process & Production > News
Curis announces allowance of US patent covering compounds targeting HDAC and PI3K activities in a single molecule
Curis, an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, has announced the receipt of a Notice of Allowance of a U.S. patent that covers a broad genus of compounds that target histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) activities in a single chemical structure including CUDC-907, Curis' oral, dual HDAC and PI3K small molecule inhibitor that is currently being studied in Phase 1 clinical trials.
Production & Manufacturing > Process & Production > News
Relypsa submits NDA for FDA clearance of hyperkalemia treatment Patiromer FOS
By PBR Staff Writer
Biopharmaceutical firm Relypsa has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) seeking clearance to market Patiromer for Oral Suspension (Patiromer FOS) to treat hyperkalemia.
Production & Manufacturing > Process & Production > News
USPTO grants Epizyme with notices of allowance for patent applications covering PRMT5 inhibitors
Epizyme, a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, has announced that the US Patent and Trademark Office has granted Notices of Allowance for US Patent Applications, Nos. 14/136,551 and 14/136,738, both entitled “PRMT5 Inhibitors and Uses Thereof.”
Production & Manufacturing > Process & Production > News
FDA clears Tonix's IND for TNX-201 to treat episodic tension-type headache
By PBR Staff Writer
The US Food and Drug Administration (FDA) has cleared Tonix Pharmaceuticals' investigational new drug (IND) application to evaluate TNX-201, a single isomer of isometheptene (IMH), to treat episodic tension-type headache.
Production & Manufacturing > Process & Production > News
TWi Biotechnology's AC-201 secures FDA orphan drug status for epidermolysis bullosa
By PBR Staff Writer
TWi Biotechnology has received the Orphan Drug designation from the US food and Drug Administration (FDA) for AC-201, a first-in-class, small molecule, to treat epidermolysis bullosa (EB).
Production & Manufacturing > Process & Production > News
Synageva begins rolling submission of BLA to FDA for sebelipase alfa to treat LAL Deficiency
By PBR Staff Writer
Synageva BioPharma has started rolling submission of a biologics license application (BLA) to the US Food and Drug Administration (FDA) for sebelipase alfa to treat patients with lysosomal acid lipase deficiency (LAL Deficiency).
Production & Manufacturing > Process & Production > News
FDA to review Eisai's sNDA for antiepileptic drug perampanel to treat PGTC seizures
By PBR Staff Writer
The US Food and Drug Administration (FDA) has accepted for review Eisai's supplemental new drug application (sNDA) for its in-house-discovered AMPA receptor antagonist perampanel to treat primary generalized tonic-clonic (PGTC) seizures.
Production & Manufacturing > Process & Production > News
Matinas submits IND for MAT9001 to treat severe hypertriglyceridemia
By PBR Staff Writer
US-based biopharmaceutical firm Matinas BioPharma Holdings has submitted an investigational new drug application (IND) for its lead drug candidate, MAT9001, to the US Food and Drug Administration (FDA) for the treatment of severe hypertriglyceridemia (TG>500mg/dL).
Production & Manufacturing > Process & Production > News
View all Process & Production news or find news targeted to your interests

Buy the latest industry research online today!
Shire Plc : Pharmaceuticals & Healthcare - Company Profile, SWOT & Financial Report 03 October 2013 This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $250